China’s Acebright Holdings is investing $1 million in NasVax Ltd for two of its treatments. One is NasVax’s Anti-CD3 technology for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. The other is its BBS technology for the treatment of Alzheimer’s disease.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000877191
China buys into Israeli treatments
This entry was posted in Economy & Business. Bookmark the permalink.